- Janice Hopkins Tanne
- 1New York
An international study of 4363 patients with rheumatoid arthritis has shown that use of almost all disease modifying agents reduces cardiovascular events (Arthritis Research and Therapy 2008;10:R30; doi: 10.1186/ar2383).
The study, which looked at disease modifying agents including methotrexate, leflunomide, glucocorticoids, sulfasalazine, and tumour necrosis factor α blockers showed that they reduced these patients’ increased risk of cardiovascular events, perhaps through an anti-inflammatory effect.
The use of malaria drugs and intramuscular gold did not change the risk of cardiovascular disease.
The study, called QUESTRA (questionnaires in standard monitoring of patients with rheumatoid arthritis programme), was led by Antonio Naranjo of the University of Las …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.